116 related articles for article (PubMed ID: 24063901)
1. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
Litwin AH; Soloway IJ; Cockerham-Colas L; Reynoso S; Heo M; Tenore C; Roose RJ
Int J Drug Policy; 2015 Oct; 26(10):1014-9. PubMed ID: 26341685
[TBL] [Abstract][Full Text] [Related]
2. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Miotto N; Mendes LC; Zanaga LP; Goncales ES; Lazarini MS; Pedro MN; Goncales FL; Stucchi RS; Vigani AG
Braz J Med Biol Res; 2016 Jun; 49(7):. PubMed ID: 27356107
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir.
Drugs R D; 2010; 10(3):179-202. PubMed ID: 20945948
[TBL] [Abstract][Full Text] [Related]
4. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol A; Rademacher K; Schafer JA
J Manag Care Pharm; 2011 Nov; 17(9):685-94. PubMed ID: 22050393
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Neukam K; Munteanu DI; Rivero-Juárez A; Lutz T; Fehr J; Mandorfer M; Bhagani S; López-Cortés LF; Haberl A; Stoeckle M; Márquez M; Scholten S; de Los Santos-Gil I; Mauss S; Rivero A; Collado A; Delgado M; Rockstroh JK; Pineda JA
PLoS One; 2015; 10(4):e0125080. PubMed ID: 25923540
[TBL] [Abstract][Full Text] [Related]
6. Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.
Henderson RR; Visaria J; Bridges GG; Dorholt M; Levin RJ; Frazee SG
J Manag Care Spec Pharm; 2014 Dec; 20(12):1227-34. PubMed ID: 25443516
[TBL] [Abstract][Full Text] [Related]
7. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M
World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
Armignacco O; Andreoni M; Sagnelli E; Puoti M; Bruno R; Gaeta GB; Perno CF; Santantonio TA; Bonfanti P; Bonora S; Borderi M; Castagna A; d'Arminio Monforte A; De Luca A; Grossi P; Guaraldi G; Maggiolo F; Mussini C; Sagnelli C; Tavio M; Torti C; Uberti-Foppa C; Andreoni M; Angarano G; Antinori A; Armignacco O; Carosi G; Chirianni A; Di Perri G; Galli M; Lazzarin A; Rizzardini G; Sagnelli E; Taliani G
New Microbiol; 2014 Oct; 37(4):423-38. PubMed ID: 25387281
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C.
Webster DP; Klenerman P; Dusheiko GM
Lancet; 2015 Mar; 385(9973):1124-35. PubMed ID: 25687730
[TBL] [Abstract][Full Text] [Related]
10. Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients.
Piekarska A; Berkan-Kawińska A; Berak H; Mazur W; Sitko M; Parfieniuk-Kowerda A; Lorenc B; Dybowska D; Janczewska E; Janocha-Litwin J; Dobracka B; Socha Ł; Tudrujek-Zdunek M; Flisiak R
Expert Rev Anti Infect Ther; 2024 May; ():1-6. PubMed ID: 38722307
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C in Argentina: epidemiology and treatment.
Gaite LA; Marciano S; Galdame OA; Gadano AC
Hepat Med; 2014; 6():35-43. PubMed ID: 24966701
[TBL] [Abstract][Full Text] [Related]
12. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
13. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
[TBL] [Abstract][Full Text] [Related]
14. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
15. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
16. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
17. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
